Physician profile
Katlin E Hunt
NPI 1487168662
$1,229.10
in general payments reported to CMS, 2019-2025
15 companies · $35.02 in 2025
The $35.02 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $972 · 2023: $68.04 · 2025: $35.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $103.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $320.76 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $192.37 | 2022-2023 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.61 | 2021-2022 | |
| Alkermes, INC. | $97.86 | 2022 | |
| Ironshore Pharmaceuticals INC. | $81.87 | 2021-2022 | |
| Corium, LLC | $78.77 | 2022 | |
| Tris Pharma INC | $77.83 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $59.84 | 2021-2022 | |
| Neos Therapeutics, LP | $48.61 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $40.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.86 | 2022-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $34.91 | 2022 | |
| Vanda Pharmaceuticals INC. | $26.69 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $17.90 | 2025 | |
| Avanir Pharmaceuticals, INC. | $15.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katlin Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.